--- title: InfinityRx named No. 156 on the 2026 Inc. 5000 list description: InfinityRx ranks No. 156 on the 2026 Inc. 5000 list, showcasing remarkable growth and innovation in claims adjudication for pharmaceutical manufacturers. image: https://www.infinityrx.com/hubfs/InfinityRx%20Inc5000%20Announcement%20Graphic.jpg --- InfinityRx made the 2026 Inc. 5000 list. [See our Inc. 5000 ranking](https://www.infinityrx.com/news-insights/infinityrx-named-to-2026-inc5000) [![infinityrx-white](https://www.infinityrx.com/hs-fs/hubfs/Logos/infinityrx-white.png?width=512&height=392&name=infinityrx-white.png)](https://www.infinityrx.com) - [Solutions](https://www.infinityrx.com/solutions) [Claims Program Administration Pharmacy and medical benefit copay through one proprietary engine.](https://www.infinityrx.com/solutions#powered-by-icp) [Access Services Verify coverage. Accelerate access.](https://www.infinityrx.com/solutions#powered-by-icp) [GTN Protection Protect access. Protect every affordability dollar.](https://www.infinityrx.com/solutions#powered-by-icp) [Data & Program Intelligence Turn claims, access, and spend data into better program decisions.](https://www.infinityrx.com/solutions#powered-by-icp) [Patient Engagement Connected communications throughout the therapy journey.](https://www.infinityrx.com/solutions#powered-by-icp) See what your affordability program isn't telling you A structured read on leakage, speed, and claim-level visibility across your portfolio. [Request a Program Assessment](https://www.infinityrx.com/request-program-assessment) [Submit an RFP →](https://www.infinityrx.com/rfp-submission) - [Insights](https://www.infinityrx.com/news-insights) [All Articles For the teams running patient access programs](https://www.infinityrx.com/news-insights) [Benefit-to-WAC Ratio Understand program stability through Benefit-to-WAC ratio](https://www.infinityrx.com/news-insights/understanding-program-sustainability-through-benefit-to-wac-ratio) [Pharmacy Monitoring Why Real-Time Visibility Beats Reactive Audits](https://www.infinityrx.com/news-insights/pharmacy-monitoring-real-time-visibility) [Unified Dual Benefit Why Pharmacy and Medical Benefits Belong on One Platform](https://www.infinityrx.com/news-insights/unified-dual-benefit-why-pharmacy-and-medical-belong-on-one-platform) [Under-Reimbursement The Gross-to-Net Leak Most Manufacturers Don't See](https://www.infinityrx.com/news-insights/under-reimbursement-the-gross-to-net-leak-most-manufacturers-dont-see) [InfinityRx named No. 156 on the 2026 Inc. 5000 list Read the announcement](https://www.infinityrx.com/news-insights/infinityrx-named-to-2026-inc5000) - [About Us](https://www.infinityrx.com/about) - [Contact Us](https://www.infinityrx.com/contact) [Request a Program Assessment](https://www.infinityrx.com/request-program-assessment) Solutions [Solutions overview](https://www.infinityrx.com/solutions) [Claims Program Administration](https://www.infinityrx.com/solutions#powered-by-icp) [Access Services](https://www.infinityrx.com/solutions#powered-by-icp) [GTN Protection](https://www.infinityrx.com/solutions#powered-by-icp) [Data & Program Intelligence](https://www.infinityrx.com/solutions#powered-by-icp) [Patient Engagement](https://www.infinityrx.com/solutions#powered-by-icp) Insights [Insights overview](https://www.infinityrx.com/news-insights) [All Articles](https://www.infinityrx.com/news-insights) [Benefit-to-WAC Ratio](https://www.infinityrx.com/news-insights/understanding-program-sustainability-through-benefit-to-wac-ratio) [Pharmacy Monitoring](https://www.infinityrx.com/news-insights/pharmacy-monitoring-real-time-visibility) [Unified Dual Benefit](https://www.infinityrx.com/news-insights/unified-dual-benefit-why-pharmacy-and-medical-belong-on-one-platform) [Under-Reimbursement](https://www.infinityrx.com/news-insights/under-reimbursement-the-gross-to-net-leak-most-manufacturers-dont-see) [About Us](https://www.infinityrx.com/about) [Contact Us](https://www.infinityrx.com/contact) [Request a Program Assessment](https://www.infinityrx.com/request-program-assessment) # InfinityRx named No. 156 on the 2026 Inc. 5000 list [David Dobson](https://www.infinityrx.com/news-insights/author/david-dobson) Aug 11, 2026 --- [Award](https://www.infinityrx.com/news-insights/tag/award) [Press Release](https://www.infinityrx.com/news-insights/tag/press-release) FOR IMMEDIATE RELEASE ## InfinityRx ranks No. 156 on the 2026 Inc. 5000 with approximately 450% three-year growth. *Bootstrapped and profitable, the pharmacist-founded patient services company was also named the No. 2 fastest-growing company in the Northeast on the 2026 Inc. Regionals list. *   **Westbury, NY — August 11, 2026** — InfinityRx today announced it has been ranked No. 156 on the 2026 Inc. 5000 list, the annual list of the fastest-growing private companies in America. The list is the most prestigious ranking of the nation's most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Past honorees include companies such as Microsoft, Meta, Chobani, Oracle, and Patagonia. The Inc. 5000 ranking follows an earlier recognition on the 2026 Inc. Regionals list, where [InfinityRx was named the No. 2 fastest-growing company in the Northeast](https://www.infinityrx.com/news-insights/infinityrx-named-2-fastest-growing-company-in-the-northeast-on-the-2026-inc.-regionals-list). The No. 156 national ranking reflects approximately 450% revenue growth from 2022 through 2025 and continued demand from pharmaceutical manufacturers for greater control, transparency, and intelligence across patient affordability programs. InfinityRx also ranked No. 2 in Biotech and Pharmaceuticals, No. 19 in New York state, and No. 17 in the New York metro area. Founded in 2021, InfinityRx builds and operates [InfinityRx Claims Processor®](https://www.infinityrx.com/solutions), its patent-protected claims adjudication platform for pharmaceutical and biotech manufacturers, rather than relying on a third-party claims processor. That owned adjudication architecture allows the company to onboard clients faster, respond to program changes in real time, and scale across therapeutic areas and brand sizes.  “Ranking No. 156 is a meaningful milestone for our team, but more importantly, it validates the model we set out to build," said Greg Savino, PharmD, co-founder and CEO of InfinityRx. "Patient affordability administration does not have to be a commodity. Manufacturers want greater control, transparency, and speed, and owning the technology that runs their programs allows us to respond differently." The company's growth has been driven by increased demand from manufacturers seeking greater control, transparency, and visibility across their affordability programs. InfinityRx has successfully migrated numerous products from other administrators in the past year while maintaining continuity of patient access.  "Affordability programs are no longer just a patient services function," Savino said. "They increasingly sit at the intersection of patient access, program sustainability, and gross-to-net performance. Our role is to give manufacturers the visibility and operating flexibility to manage all three."  Savino also pointed to what the ranking doesn't capture. "One challenge we faced when building InfinityRx was offering a service that was perceived to be a commodity. We've been breaking that concept since we entered this market, and we've demonstrated that there is true value in selecting the proper affordability partner for your patient support program."  InfinityRx has achieved that growth while remaining bootstrapped and profitable. Its team spans software engineering, claims operations, program management, compliance, and analytics. Built around InfinityRx Claims Processor, the company's platform brings pharmacy and medical benefit adjudication, accumulator and maximizer identification and mitigation, pharmacy monitoring, program integrity analytics, and [real-time reporting](https://www.infinityrx.com/news-insights/pharmacy-monitoring-real-time-visibility) onto a single operating infrastructure.  This year's Inc. 5000 recognizes a new class of companies redefining what growth looks like. From AI and advanced manufacturing to healthcare, consumer products, and professional services, these businesses are expanding their impact, creating jobs and proving that entrepreneurial ambition continues to fuel the U.S. economy. Among the 5,000 companies on the list, the median three-year revenue growth rate was 130%, and those companies have collectively added more than 627,208 jobs to the U.S. economy over the past three years. For the full Inc. 5000 list, honoree company profiles, and a searchable database by industry and location, please visit: [www.inc.com/inc5000](http://www.inc.com/inc5000). "Every company on the Inc. 5000 has a story of perseverance, smart decision making, and a refusal to sit still," says Mike Hofman, editor-in-chief of Inc. "Their growth reflects more than strong financial performance--it reflects creativity, resilience, and the customer focus required to build companies that make a lasting impact. We congratulate all honorees on this significant achievement." Inc. 5000 List Methodology  Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2022 to 2025. To qualify, companies must have been founded and generating revenue by March 31, 2022. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2025. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2022 is $100,000; the minimum for 2025 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About InfinityRx  InfinityRx is a patient affordability and program intelligence company helping pharmaceutical and biotech manufacturers administer, monitor, and optimize patient support across pharmacy and medical benefits. Founded in 2021 and headquartered in Westbury, New York, the company owns and operates InfinityRx Claims Processor®, its patent-protected claims adjudication platform. InfinityRx [unifies pharmacy and medical benefit adjudication](https://www.infinityrx.com/news-insights/unified-dual-benefit-why-pharmacy-and-medical-belong-on-one-platform), copay program administration, accumulator and maximizer identification and mitigation, program integrity monitoring, and real-time reporting on a single operating infrastructure. Learn more about InfinityRx at www.infinityrx.com  or [follow us on LinkedIn @InfinityRx](https://www.linkedin.com/company/infinityrx). About Inc.  Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit [www.inc.com](http://www.inc.com). — ### — ****Media Contact**** [mailto:david@infinityrx.com](mailto:david@infinityrx.com) David Dobson[mailto:david@infinityrx.com](mailto:david@infinityrx.com)Director, Brand & Marketing[mailto:david@infinityrx.com](mailto:david@infinityrx.com)InfinityRx [david@infinityrx.com](mailto:david@infinityrx.com) InfinityRx · 1600 Stewart Avenue, Suite 404 · Westbury, NY 11590 ---   About the Author ### [David Dobson](https://www.infinityrx.com/news-insights/author/david-dobson) Director, Marketing & Brand David Dobson is Director of Marketing & Brand at InfinityRx, where he helps pharmaceutical manufacturers understand the technology and operational challenges behind patient affordability programs. His background spans brand and creative marketing at ConnectiveRx, creative account strategy at Thermo Fisher Scientific, and demand generation for Net Health's provider audiences, giving him a view across the technology companies, providers, and manufacturers that make healthcare work. [Connect on LinkedIn](https://www.linkedin.com/in/daviddobson/)     ## Related Insights [![InfinityRx Wins Gold at the 2026 American Business Awards® for Health and Pharmaceutical Services](https://www.infinityrx.com/hs-fs/hubfs/InfinityRx%20Wins%202026%20American%20Business%20Awards%20for%20Health%20and%20Pharma.png?width=650&height=364&name=InfinityRx%20Wins%202026%20American%20Business%20Awards%20for%20Health%20and%20Pharma.png)](https://www.infinityrx.com/news-insights/infinityrx-wins-gold-at-the-2026-american-business-awards-for-health-and-pharmaceutical-services) Award ### [InfinityRx Wins Gold at the 2026 American Business Awards® for Health and Pharmaceutical Services](https://www.infinityrx.com/news-insights/infinityrx-wins-gold-at-the-2026-american-business-awards-for-health-and-pharmaceutical-services) [![Understanding program sustainability through Benefit-to-WAC ratio](https://www.infinityrx.com/hs-fs/hubfs/Benefit%20to%20WAC%20%20ratio%20and%20program%20sustainability.jpg?width=650&height=364&name=Benefit%20to%20WAC%20%20ratio%20and%20program%20sustainability.jpg)](https://www.infinityrx.com/news-insights/understanding-program-sustainability-through-benefit-to-wac-ratio) Claims Adjudication ### [Understanding program sustainability through Benefit-to-WAC ratio](https://www.infinityrx.com/news-insights/understanding-program-sustainability-through-benefit-to-wac-ratio) Gross-to-Net ### [The Vendors-of-Vendors Problem: Why Fragmented Stacks Cost You More Than You Think](https://www.infinityrx.com/news-insights/the-vendors-of-vendors-problem-why-fragmented-stacks-cost-you-more-than-you-think) [![InfinityRx](https://www.infinityrx.com/hs-fs/hubfs/InfinityRx%20logo%20white.png?width=300&height=52&name=InfinityRx%20logo%20white.png "InfinityRx")](https://infinityrx.com) InfinityRx helps pharmaceutical manufacturers administer pharmacy and medical benefit affordability programs, protect GTN performance, and turn claim-level data into better program decisions through InfinityRx Claims Processor®, the adjudication engine we own.  Built in New York. Explore - [Solutions](https://www.infinityrx.com/solutions) - [Insights](https://www.infinityrx.com/news-insights) - [Submit an RFP](https://www.infinityrx.com/rfp-submission) - [Request a Program Assessment](https://www.infinityrx.com/request-program-assessment) Company - [About Us](https://www.infinityrx.com/about) - [Contact Us](https://www.infinityrx.com/contact) - [Careers](https://www.linkedin.com/company/infinityrx/jobs) - [Follow Us](https://www.linkedin.com/company/infinityrx) SOC 2 · Type I + Type II Security, Availability, Confidentiality SOC 1 · Type I + Type II Financial Reporting Controls HIPAA Compliant PHI Handling Framework · Full Audit Logging --- © InfinityRx, LLC | All rights reserved. [Terms of Use](https://www.infinityrx.com/terms-of-use) • [Privacy Policy](https://www.infinityrx.com/privacy-policy) • [Cookie Policy](https://www.infinityrx.com/cookies-policy) • [Do Not Sell My Personal Information](https://www.infinityrx.com/do-not-sell-my-personal-data) • [Accessibility](https://www.infinityrx.com/accessibility) ![back-to-top](https://f.hubspotusercontent00.net/hubfs/7712601/back-to-top.png) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "David Dobson", "url" : "https://www.infinityrx.com/news-insights/author/david-dobson" }, "dateModified" : "2026-09-24T17:28:37.903Z", "datePublished" : "2026-08-11T11:00:00.000Z", "headline" : "InfinityRx named No. 156 on the 2026 Inc. 5000 list", "image" : [ "https://www.infinityrx.com/hubfs/InfinityRx%20Inc5000%20Announcement%20Graphic.jpg" ], "mainEntityOfPage" : { "@id" : "https://www.infinityrx.com/news-insights/infinityrx-named-to-2026-inc5000", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://www.infinityrx.com/hubfs/infinityrx_logo_black.png" } } } ``` ```json { "@context" : "https://schema.org", "@type" : "Organization", "logo" : "https://www.infinityrx.com/hubfs/infinityrx_logo_black.png", "name" : "InfinityRx", "sameAs" : [ "https://www.linkedin.com/company/infinityrx" ], "url" : "https://www.infinityrx.com" } ``` ```json { "@context" : "https://schema.org", "@type" : "Person", "jobTitle" : "Director, Marketing & Brand", "name" : "David Dobson", "sameAs" : [ "https://www.linkedin.com/in/daviddobson/" ], "url" : "https://www.infinityrx.com/news-insights/author/david-dobson" } ```